Lovelace (November 12, 2022) reported on covid-19 vaccine recipient Mr. Da’Vion Miller, who developed myocarditis shortly after his second covid-19 vaccine shot. The young man of 22 years of age experienced “chest pain two days after getting vaccinated, followed by fatigue, shortness of breath and dizziness.” As a result, Da’Vion’s doctor advised him not to receive a second dose of the Pfizer or Moderna vaccines. A tiny group in the United States has experienced myocarditis following vaccination with the Pfizer-BioNTech or Moderna. Both vaccines have mRNA technology.
Myocarditis is an inflammation and damage of the heart muscle known as the myocardium. Most commonly caused by a viral infection, but it can also be an infection of bacteria, fungi, parasites, or a reaction to a drug. Pericarditis is an Inflammation of the pericardium (thin membrane around the heart), causing chest pain. The CDC has identified at least 1,000 vaccine-related heart conditions(myocarditis or pericarditis) in children under age 18. Most vaccine recipients who developed the condition have fully recovered, although research has only looked at how well they do after several months. However, doctors wonder if it can cause permanent damage to the heart.
U.S. research is tracking adverse health effects that may appear in the years following a diagnosis of vaccine-associated heart problems. Moderna has already launched two trials, and Pfizer confirmed that at least one of its trials, including up to 500 teens and young adults under age 21, will begin very soon. In addition, the Food and Drug Administration has required drugmakers to conduct several studies of the long-term impacts of mRNA vaccines on heart inflammation. Some trials will follow those who developed the condition for as long as five years. The tests will be monitored for myocarditis. The chance of having myocarditis after vaccination is slight.
A study by Canadian researchers in the Journal of the American College of Cardiology found that men younger than 40 who got the Moderna vaccine had the highest risk of heart issues, usually within 21 days after the second dose. The study was observational, one of only a few studies to compare the risk of myocarditis between the Pfizer and the Moderna vaccines. The Johnson and Johnson vaccine and the Novavax vaccine makers reported no heart inflammation concerns in their patients during clinical trials of its vaccine. New reports and findings will unfold in the upcoming years 2023-2025.
The Narrative Matters!
Klein, N. (October 21, 2021). Myocarditis Analyses in the Vaccine Safety Datalink: Rapid Cycle Analyses and “Head to Head” Product Comparisons. Update on myocarditis following mRNA COVID-19 vaccination (cdc.gov)
Lovelace, B. ( November 12, 2022). Myocarditis after Covid vaccination: Research on possible long-term risks underway. Myocarditis after Covid vaccine: Research on long-term effects underway (nbcnews.com)
Shimabukuro, T. (July 23, 2022).Update on myocarditis following mRNA COVID-19 vaccination. Update on myocarditis following mRNA COVID-19 vaccination (cdc.gov)
Su, J. (October 21, 2021). Myopericarditis following Coivd-19 vaccination: Updates from the Vaccine Adverse Event Reporting (VAERS) Update on myocarditis following mRNA COVID-19 vaccination (cdc.gov)